SGS


COVID-19's benefits are likely but not for now

10/08/20 -"We have revised our earnings forecasts in the light of the group’s H1 20 results. Management would not provide any specific guidance for the year, which indicates the very little visibility that the ..."

Pages
50
Language
English
Published on
10/08/20
You may also be interested by these reports :
12/04/24
At its CMD, Bureau Veritas unveiled a new set of financial targets. Under its new strategy, the group is targeting high single-digit revenue growth ...

11/03/24
Securitas reiterated its mid-term financial goals at its Capital Market Day. The security services market is changing with the expansion of ...

07/03/24
Rentokil initial reported better-than-expected FY23 results, with profitability ahead of street and our expectations. Organic revenue increased 4.9% ...

05/03/24
We have materially cut our EPS 2024 and 2025 estimates as the anticiapted adjusted operating margin recovery did not pan out in 2023. In 2023, not ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO